Entera Bio Ltd.
ENTXNASDAQHealthcare● Active
$1.20
+$0.02(+1.69%)
Market Cap$59148240
P/E Ratio—
52W High$3.22
52W Low$0.91
Entera Bio Ltd. (ENTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ENTX · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 8, 2026EPS Actual
-$0.07
Est. -$0.08 · +12.5%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 8, 2026
After Market Close
▲ Beat EPS🔥 6-Quarter EPS Beat Streak
ENTX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 14, 2026 | -$0.08 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 8, 2026 | -$0.08 | -$0.07 | +12.5% | — | — | — |
| ▲ Q1 FY2026 | Mar 27, 2026 | -$0.09 | -$0.07 | +22.2% | — | — | — |
| ▲ Q4 FY2025 | Nov 14, 2025 | -$0.09 | -$0.07 | +22.2% | — | — | — |
| ▲ Q3 FY2025 | Aug 8, 2025 | -$0.11 | -$0.06 | +45.5% | — | — | — |
| ▲ Q2 FY2025 | May 9, 2025 | -$0.07 | -$0.06 | +14.3% | $0.00B | — | — |
| ▲ Q1 FY2025 | Mar 28, 2025 | -$0.08 | -$0.06 | +25.0% | $0.00B | $0.00B | +105.0% |
| ▼ Q4 FY2024 | Nov 8, 2024 | -$0.05 | -$0.08 | -60.0% | $0.00B | $0.00B | +5.0% |
Q3 FY2026
Aug 14, 2026
EPS Actual
—
EPS Est.
-$0.08
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 8, 2026Beat
EPS Actual
-$0.07
EPS Est.
-$0.08
EPS Surpr.
+12.5%
Revenue
—
Q1 FY2026
Mar 27, 2026Beat
EPS Actual
-$0.07
EPS Est.
-$0.09
EPS Surpr.
+22.2%
Revenue
—
Q4 FY2025
Nov 14, 2025Beat
EPS Actual
-$0.07
EPS Est.
-$0.09
EPS Surpr.
+22.2%
Revenue
—
Q3 FY2025
Aug 8, 2025Beat
EPS Actual
-$0.06
EPS Est.
-$0.11
EPS Surpr.
+45.5%
Revenue
—
Q2 FY2025
May 9, 2025Beat
EPS Actual
-$0.06
EPS Est.
-$0.07
EPS Surpr.
+14.3%
Revenue
$0.00B
Q1 FY2025
Mar 28, 2025Beat
EPS Actual
-$0.06
EPS Est.
-$0.08
EPS Surpr.
+25.0%
Revenue
$0.00B
Q4 FY2024
Nov 8, 2024Miss
EPS Actual
-$0.08
EPS Est.
-$0.05
EPS Surpr.
-60.0%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.16 | $-0.16 | $-0.16 | 1 |
| Q3 FY2027 | $-0.15 | $-0.15 | $-0.15 | 1 |
| Q2 FY2027 | $-0.13 | $-0.13 | $-0.13 | 1 |
| Q1 FY2027 | $-0.13 | $-0.13 | $-0.13 | 1 |
| Q4 FY2026 | $-0.09 | $-0.09 | $-0.09 | 1 |
| Q3 FY2026 | $-0.08 | $-0.08 | $-0.08 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 8, 2026 | +12.5% | $1.37 | $1.30 | -5.11% |
| ▲ Q1 FY2026 | Mar 27, 2026 | +22.2% | $1.03 | $1.13 | +9.71% |
| ▲ Q4 FY2025 | Nov 14, 2025 | +22.2% | $2.74 | $2.71 | -1.09% |
| ▲ Q3 FY2025 | Aug 8, 2025 | +45.5% | $1.80 | $1.82 | +1.11% |
| ▲ Q2 FY2025 | May 9, 2025 | +14.3% | $2.22 | $2.15 | -3.15% |
| ▲ Q1 FY2025 | Mar 28, 2025 | +25.0% | $1.80 | $1.75 | -2.78% |
| ▼ Q4 FY2024 | Nov 8, 2024 | -60.0% | $1.75 | $1.72 | -1.71% |
| ▲ Q3 FY2024 | Aug 9, 2024 | +0.0% | $1.60 | $1.60 | +0.00% |
Q2 FY2026-5.11%
Report Date
May 8, 2026
EPS Beat/Miss
+12.5%
Price Before
$1.37
Price After
$1.30
Q1 FY2026+9.71%
Report Date
Mar 27, 2026
EPS Beat/Miss
+22.2%
Price Before
$1.03
Price After
$1.13
Q4 FY2025-1.09%
Report Date
Nov 14, 2025
EPS Beat/Miss
+22.2%
Price Before
$2.74
Price After
$2.71
Q3 FY2025+1.11%
Report Date
Aug 8, 2025
EPS Beat/Miss
+45.5%
Price Before
$1.80
Price After
$1.82
Q2 FY2025-3.15%
Report Date
May 9, 2025
EPS Beat/Miss
+14.3%
Price Before
$2.22
Price After
$2.15
Q1 FY2025-2.78%
Report Date
Mar 28, 2025
EPS Beat/Miss
+25.0%
Price Before
$1.80
Price After
$1.75
Q4 FY2024-1.71%
Report Date
Nov 8, 2024
EPS Beat/Miss
-60.0%
Price Before
$1.75
Price After
$1.72
Q3 FY2024+0.00%
Report Date
Aug 9, 2024
EPS Beat/Miss
+0.0%
Price Before
$1.60
Price After
$1.60
Avg Beat Reaction-0.19%
Avg Miss Reaction-1.71%
Beat Rate7 / 8 quarters
Largest Move+9.71% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ENTX ends December
Entera Bio Ltd. (ENTX) most recently reported earnings on May 8, 2026 for Q2 FY2026, posting EPS of $-0.07 — beating the analyst consensus of $-0.08 by +12.5%. ENTX has beaten EPS estimates for 6 consecutive quarters. The next ENTX earnings date is expected around September 1, 2026.
Each quarter, investors track ENTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ENTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ENTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ENTX earnings · 5 questionsEntera Bio Ltd.'s next earnings report is expected around September 1, 2026. ENTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ENTX historically reports after market close (AMC).
ENTX earnings datewhen is ENTX earningsENTX next earnings datewhen does ENTX report earningsENTX earnings calendar
▸ Source: FMP · Entera Bio Ltd. SEC filings · US GAAP · Entera Bio Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026